We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more here.Close Me
The Biotechnology and Medical Devices industries saw venture
capitalists invest a total of $1.5 billion in the first quarter of
2012. While Medical Device venture funding accelerated, it could
not offset the slowdown in Biotechnology and the first quarter of
2012 decreased 22% from the fourth quarter of 2011. Deal volume was
also down from the previous quarter, dropping 11% to 171 deals.
This quarterly summary includes data on where venture capital
investments and funding were made, the nature of transactions that
took place as well as the geographic distribution of funding for
the biotechnology and medical device sectors during the first
quarter 2012.
Mobile technology has long been viewed as an innovation with
much potential to transform the healthcare industry and address
long-standing issues. Yet there is little understanding of how to
harness its power or develop business models that work.
Emerging mHealth: Paths for Growth, an Economist Intelligence
Unit report commissioned by PwC examines the current state and
potential of mHealth in developed and emerging markets, the ongoing
barriers to its adoption and the implications for companies in the
field.
Key insights include:
Consumer behaviour — their expectations and
preferences, and how mHealth can drive change
Ingredients for successful mHealth business models
The impact of mobile technology, and why it will become one of
the most dominant models of delivery in healthcare
The House Ways and Means Committee yesterday voted 23 to 11 to
approve the "Protect Medical Innovation Act" (H.R. 436),
a bill to repeal a medical device excise tax scheduled to be
effective in 2013 under the 2010 health care law. The Ways and
Means Committee also approved a bill providing for a $500 taxable
cash-out exception from flexible spending account
"use-it-or-lose-it" rules (H.R. 1004); a bill repealing a
restriction on use of flexible spending accounts to purchase
over-the-counter drugs (H.R. 5842); and a bill modifying health
savings account rules (H.R. 5858). The full House is expected to
vote on the four health care-related measures as early as next
week.
In the face of business model challenges, declining R&D
budgets, and expirations of blockbuster patents, the
pharmaceuticals and life sciences industry is among several that
may benefit from a proposed US "patent box" tax regime. A
US patent box — deriving its name from a box on the
corporate tax form — would reward companies for
commercializing innovative products by taxing the profits on their
sale at a reduced rate. Such a regime in the United States could
substantially reduce what now ranks as the highest tax rate among
the Organization for Economic Cooperation and Development (OECD)
countries for intellectual property (IP) income.
Supporters of a US patent box regime suggest, among other
things, that it would further competitiveness of US companies and
encourage the development and retention of IP within US borders. As
some countries have done, the scope of the patent box regime could
be expanded beyond patents to encourage a broader array of
innovation-based intellectual property.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The Supreme Court has rendered its decision in Cojocaru v. British Columbia Women's Hospital and Health Centre, a case concerned with the propriety of judicial adoption verbatim of counsel's submissions in the Court's decision.
Canadians like to believe that we have the best healthcare system in the world, however, a survey of primary care physicians indicates that Canadian physicians disagree.
In an industry where one out of 10,000 drugs makes it to market, and where many drugs fail after millions of dollars of investment, one of the challenges is to create an environment that enhances the chance of success and mitigates the high cost of failures.
On April 26, 2013, Health Canada published a notice to inform clinical trial sponsors that information about Clinical Trial Applications ("CTAs") will be published.
To everyone’s surprise, the government has announced its intention to repeal the famous standard container size regulations that are set out in the Processed Products Regulations (PPR).
Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement.
Canada’s 1994 NAFTA
and
Miriam Pozza 
